趋化因子用于结核病诊断的研究进展

doi:10.19982/j.issn.1000-6621.20220374

摘要/Abstract

摘要：

趋化因子是一类高度保守的蛋白质家族,参与多种生物过程,包括趋化细胞迁移、免疫细胞脱颗粒、造血和血管生成,在人体免疫系统中发挥重要作用。当机体感染结核分枝杆菌后,趋化因子及其受体的表达发生变化,其中多种趋化因子具有作为结核病诊断的生物学标志物的潜力。笔者总结了近些年趋化因子之于结核病诊断相关的研究,对CC趋化因子家族、CXC趋化因子家族及CXCL趋化因子家族中的部分因子及其受体的诊断学价值进行综述,探讨其在结核病诊断中的应用潜力,为结核病的诊断以及预后评估提供有价值的临床参考。

关键词: 炎症趋化因子类, 结核, 诊断, 敏感性与特异性, 生物学标记

Abstract:

Chemokines are a family of highly conserved proteins involved in many biological processes, including chemotactic cell migration, immune cell degranulation, hematopoiesis and angiogenesis, and play an important role in the human immune system. After being infected with Mycobacterium tuberculosis, the expression of chemokines and their receptors changes, and many chemokines have the potential to be used as biomarkers for the diagnosis of tuberculosis. The authors summarize the recent studies on chemokines in the diagnosis of tuberculosis, review the diagnostic value of several important chemokines from CC chemokine family, CXC chemokine family, CXCL chemokine family and their receptors, explore the application potential in the diagnosis of tuberculosis and provide valuable clinical reference for the diagnosis and prognosis assessment of tuberculosis in the future.

Key words: Chemokines, Tuberculosis, Diagnosis, Sensitivity and Specificity, Biological Markers

中图分类号:

马子淳, 尚媛媛, 逄宇, 李姗姗. 趋化因子用于结核病诊断的研究进展[J]. 中国防痨杂志, 2023, 45(3): 305-310. doi: 10.19982/j.issn.1000-6621.20220374

Ma Zichun, Shang Yuanyuan, Pang Yu, Li Shanshan. Research progress of chemokines in the diagnosis of tuberculosis[J]. Chinese Journal of Antituberculosis, 2023, 45(3): 305-310. doi: 10.19982/j.issn.1000-6621.20220374

参考文献 43

[1]	Xu JC, Li ZY, Chen XN, et al. More significance of TB-IGRA except for the diagnose of tuberculosis. J Clin Lab Anal, 2018, 32(1): e22183. doi:10.1002/jcla.22183. doi: 10.1002/jcla.22183 URL
[2]	Acharya B, Acharya A, Gautam S, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep, 2020, 47(5): 4065-4075. doi:10.1007/s11033-020-05413-7. doi: 10.1007/s11033-020-05413-7 URL
[3]	Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol, 2007, 25: 787-820. doi:10.1146/annurev.immunol.24.021605.090529. doi: 10.1146/annurev.immunol.24.021605.090529 pmid: 17291188
[4]	Kumar NP, Moideen K, Nancy A, et al. Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis. Sci Rep, 2019, 9(1): 18217. doi:10.1038/s41598-019-54803-w. doi: 10.1038/s41598-019-54803-w pmid: 31796883
[5]	Miller MC, Mayo KH. Chemokines from a Structural Perspective. Int J Mol Sci, 2017, 18(10): 2088. doi:10.3390/ijms18102088. doi: 10.3390/ijms18102088
[6]	Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity, 2012, 36(5): 705-716. doi:10.1016/j.immuni.2012.05.008. doi: 10.1016/j.immuni.2012.05.008 pmid: 22633458
[7]	黎友伦, 罗永艾, 王国治. 细胞因子及其受体在结核免疫中的作用. 国外医学(内科学分册), 2005, 32(4): 146-149, 167.
[8]	Gustavsson M. New insights into the structure and function of chemokine receptor: chemokine complexes from an experimental perspective. J Leukoc Biol, 2020, 107(6): 1115-1122. doi:10.1002/JLB.2MR1219-288R. doi: 10.1002/JLB.2MR1219-288R URL
[9]	Domingo-Gonzalez R, Prince O, Cooper A, et al. Cytokines and Chemokines in Mycobacterium tuberculosis Infection. Microbiol Spectr, 2016, 4(5). doi:10.1128/microbiolspec.TBTB2-0018-2016. doi: 10.1128/microbiolspec.TBTB2-0018-2016
[10]	李瑞雪, 杜娟, 程义局. 趋化因子与结核病的关系研究进展. 医学综述, 2021, 27(20): 3963-3968. doi:10.3969/j.issn.1006-2084.2021.20.003. doi: 10.3969/j.issn.1006-2084.2021.20.003
[11]	Monin L, Khader SA. Chemokines in tuberculosis: the good, the bad and the ugly. Semin Immunol, 2014, 26(6): 552-558. doi:10.1016/j.smim.2014.09.004. doi: 10.1016/j.smim.2014.09.004 pmid: 25444549
[12]	Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis Infections. Microbiol Spectr, 2019, 7(4). doi:10.1128/microbiolspec.GPP3-0022-2018. doi: 10.1128/microbiolspec.GPP3-0022-2018
[13]	Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J, 2018, 285(16): 2944-2971. doi:10.1111/febs.14466. doi: 10.1111/febs.14466 pmid: 29637711
[14]	Chendi BH, Tveiten H, Snyders CI, et al. CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. J Infect, 2021, 83(4): 433-443. doi:10.1016/j.jinf.2021.07.036. doi: 10.1016/j.jinf.2021.07.036 pmid: 34333033
[15]	王晓蕾. 结核病感染免疫相关因子IL-10的表达调控及MCP-1基因多态性的研究. 济南: 山东大学, 2018.
[16]	Kipnis A, Basaraba RJ, Orme IM, et al. Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis. Immunology, 2003, 109(4): 547-551. doi:10.1046/j.1365-2567.2003.01680.x. doi: 10.1046/j.1365-2567.2003.01680.x pmid: 12871221
[17]	Biswas SK, Mittal M, Sinha E, et al. Exploring the Role of C-C Motif Chemokine Ligand-2 Single Nucleotide Polymorphism in Pulmonary Tuberculosis: A Genetic Association Study from North India. J Immunol Res, 2020, 2020: 1019639. doi:10.1155/2020/1019639. doi: 10.1155/2020/1019639
[18]	Kumar NP, Moideen K, Nancy A, et al. Plasma Chemokines Are Baseline Predictors of Unfavorable Treatment Outcomes in Pulmonary Tuberculosis. Clin Infect Dis, 2021, 73(9): e3419-e3427. doi:10.1093/cid/ciaa1104. doi: 10.1093/cid/ciaa1104 pmid: 32766812
[19]	Joosten SA, van Meijgaarden KE, Savage ND, et al. Identification of a human CD8⁺ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A, 2007, 104(19): 8029-8034. doi:10.1073/pnas.0702257104. doi: 10.1073/pnas.0702257104 URL
[20]	Phalane KG, Kriel M, Loxton AG, et al. Differential expression of host biomarkers in saliva and serum samples from individuals with suspected pulmonary tuberculosis. Mediators Inflamm, 2013, 2013: 981984. doi:10.1155/2013/981984. doi: 10.1155/2013/981984
[21]	Sutherland JS, Mendy J, Gindeh A, et al. Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis. Tuberculosis (Edinb), 2016, 96: 31-36. doi:10.1016/j.tube.2015.10.011. doi: 10.1016/j.tube.2015.10.011 URL
[22]	Akashi S, Suzukawa M, Takeda K, et al. IL-1RA in the supernatant of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus is useful for discriminating active tuberculosis from latent infection. J Infect Chemother, 2021, 27(4): 617-624. doi:10.1016/j.jiac.2020.11.023. doi: 10.1016/j.jiac.2020.11.023 pmid: 33317988
[23]	乔敏, 李姗姗, 刘荣梅, 等. CC趋化因子和CXC趋化因子及其受体在结核分枝杆菌感染免疫应答中作用的研究进展. 细胞与分子免疫学杂志, 2021, 37(4): 373-377.
[24]	Sheng YF, Qi Q. Association of chemotactic chemokine ligand 5 rs2107538 polymorphism with tuberculosis susceptibility: A meta-analysis. Innate Immun, 2020, 26(5): 358-363. doi:10.1177/1753425919891662. doi: 10.1177/1753425919891662 URL
[25]	Pydi SS, Ghousunnissa S, Devalraju KP, et al. Down regulation of RANTES in pleural site is associated with inhibition of antigen specific response in tuberculosis. Tuberculosis (Edinb), 2019, 116S: S123-S130. doi:10.1016/j.tube.2019.04.020. doi: 10.1016/j.tube.2019.04.020
[26]	Wu CL, Yin R, Wang SN, et al. A Review of CXCL 1 in Cardiac Fibrosis. Front Cardiovasc Med, 2021, 8: 674498. doi:10.3389/fcvm.2021.674498. doi: 10.3389/fcvm.2021.674498 URL
[27]	Koyuncu D, Niazi MKK, Tavolara T, et al. CXCL1: A new diagnostic biomarker for human tuberculosis discovered using Diversity Outbred mice. PLoS Pathog, 2021, 17(8): e1009773. doi:10.1371/journal.ppat.1009773. doi: 10.1371/journal.ppat.1009773 URL
[28]	Krupa A, Fol M, Dziadek BR, et al. Binding of CXCL8/IL-8 to Mycobacterium tuberculosis Modulates the Innate Immune Response. Mediators Inflamm, 2015, 2015: 124762. doi:10.1155/2015/124762. doi: 10.1155/2015/124762
[29]	邢志伟, 张珣, 王红, 等. CXCL8及其受体在肺结核诊断中的临床应用. 河北医科大学学报, 2020, 41(10): 1176-1180. doi:10.3969/j.issn.1007-3205.2020.10.013. doi: 10.3969/j.issn.1007-3205.2020.10.013
[30]	Yao X, Liu Y, Liu Y, et al. Multiplex analysis of plasma cytokines/chemokines showing different immune responses in active TB patients, latent TB infection and healthy participants. Tuberculosis (Edinb), 2017, 107: 88-94. doi:10.1016/j.tube.2017.07.013. doi: 10.1016/j.tube.2017.07.013 URL
[31]	Koper OM, Kamińska J, Sawicki K, et al. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. Adv Clin Exp Med, 2018, 27(6): 849-856. doi:10.17219/acem/68846. doi: 10.17219/acem/68846 pmid: 29893515
[32]	Shang X, Wang L, Liu Y, et al. Diagnostic value of CXCR3 and its ligands in spinal tuberculosis. Exp Ther Med, 2021, 21(1): 73. doi:10.3892/etm.2020.9505. doi: 10.3892/etm.2020.9505 pmid: 33365073
[33]	Korma W, Mihret A, Chang Y, et al. Antigen-Specific Cytokine and Chemokine Gene Expression for Diagnosing Latent and Active Tuberculosis. Diagnostics (Basel), 2020, 10(9): 716. doi:10.3390/diagnostics10090716. doi: 10.3390/diagnostics10090716
[34]	Qiu X, Xiong T, Su X, et al. Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis. BMC Infect Dis, 2019, 19(1): 924. doi:10.1186/s12879-019-4466-5. doi: 10.1186/s12879-019-4466-5 pmid: 31666025
[35]	Chung WY, Lee KS, Park JH, et al. TB Antigen-Stimulated CXCR3 Ligand Assay for Diagnosis of Tuberculous Lymphadenitis. Int J Environ Res Public Health, 2021, 18(15): 8020. doi:10.3390/ijerph18158020. doi: 10.3390/ijerph18158020 URL
[36]	魏兰, 贾新转, 秦学博, 等. 血清CXC趋化因子受体3配体检测在活动性肺结核诊断中的价值. 中国防痨杂志, 2019, 41(11): 1167-1172. doi:10.3969/j.issn.1000-6621.2019.11.005. doi: 10.3969/j.issn.1000-6621.2019.11.005
[37]	Lee K, Chung W, Jung Y, et al. CXCR3 ligands as clinical markers for pulmonary tuberculosis. Int J Tuberc Lung Dis, 2015, 19(2): 191-199. doi:10.5588/ijtld.14.0525. doi: 10.5588/ijtld.14.0525 pmid: 25574918
[38]	Bellamri N, Viel R, Morzadec C, et al. TNF-α and IL-10 Control CXCL 13 Expression in Human Macrophages. J Immunol, 2020, 204(9): 2492-2502. doi:10.4049/jimmunol.1900790. doi: 10.4049/jimmunol.1900790
[39]	Ardain A, Domingo-Gonzalez R, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature, 2019, 570(7762): 528-532. doi:10.1038/s41586-019-1276-2. doi: 10.1038/s41586-019-1276-2 URL
[40]	Jiang J, Cao Z, Qu J, et al. PD-1^- expressing MAIT cells from patients with tuberculosis exhibit elevated production of CXCL13. Scand J Immunol, 2020, 91(4): e12858. doi:10.1111/sji.12858. doi: 10.1111/sji.12858
[41]	Estévez O, Anibarro L, Garet E, et al. Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection. PLoS One, 2020, 15(7): e0235859. doi:10.1371/journal.pone.0235859. doi: 10.1371/journal.pone.0235859 URL
[42]	Cormican S, Griffin MD. Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease? Front Immunol, 2021, 12: 664202. doi:10.3389/fimmu.2021.664202. doi: 10.3389/fimmu.2021.664202 URL
[43]	Mota CMD, Antunes-Rodrigues J, Branco LGS. Central fractalkine stimulates central prostaglandin E2 production and induces systemic inflammatory responses. Brain Res Bull, 2018, 140: 311-317. doi:10.1016/j.brainresbull.2018.05.024. doi: 10.1016/j.brainresbull.2018.05.024 URL